Immuron (NASDAQ: IMRN) is up 71% this morning on the announcement that the FDA is to allow the company to continue to push its diarrhoea drug through the testing process. This has been on hold since last summer. The real point that we should take from this is how much the valuation of any research or development pharma company depends upon those reactions of the FDA. It might not be the world's swiftest bureaucracy, nor the best - and it's near certain that its incentives are wrong - but it is still absolutely vital to this industry.
Note that this 75% increase in value isn't because the FDA has passed the treatment for sale. Nothing so important as that - they're merely allowed to continue trying to develop it.

Immuron stock price from NASDAQ
The specific problem Immuron had was back in summer 2022, when the FDA said that:”The FDA had notified the company and the US Naval Medical Research Center (NMRC) in July 2022 of insufficient information in the investigational new drug (IND) application for a new oral therapeutic targeting Campylobacter and ETEC.” The next step was that a meeting was had in Dec 2022 - yes, 6 months later just for a meeting - where matters were discussed and the FDA outlined what was necessary. Another 5 months later, those changes have been made and so Immuron will now be able to continue to test the drug: “Immuron (NASDAQ:IMRN) said the U.S. Food and Drug Administration (FDA) removed a clinical hold on the start of trials of an oral antibacterial drug for preventing infectious diarrhea.”
One way to think of this is that the FDA prevented even testing of a drug to treat a serious problem for a year simply because the FDA didn't like the paperwork. Plus, obviously, it took a year to pleasure the FDA over the paperwork. This would also be a fair and accurate view too. Perhaps it would be possible for the wit of man to design a better system.
What we as investors need to realise is that the FDA does just rule this area of the economy and they do so in this manner. Just to add to the risks of investing in the pharma development sector.